Preferred Label : HLA-A2-Binding TYR/MART-1/gp100 Multipeptide-Pulsed Autologous Dendritic Cell Vaccine;
NCIt definition : A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with
human leukocyte antigen (HLA)-A2-restricted melanoma-associated antigen peptides tyrosinase
(TYR), MART-1(melanoma antigen recognized by T-cells) and melanoma antigen glycoprotein
100 (gp100), with potential immunomodulating and antineoplastic activity. Upon vaccination,
HLA-A2-binding TYR/MART-1/gp100 multipeptide-pulsed autologous dendritic cell vaccine
may stimulate the host immune system to mount an anti-tumoral cytotoxic T lymphocyte
(CTL) and antibody responses against Tyr-, MART-1 and gp100-expressing cancer cells,
resulting in tumor cell lysis. HLA-A2 is an MHC class I molecule that presents antigenic
peptides to CD8 T cells; epitope design restricted to epitopes that bind most efficiently
to HLA-A2 may improve antigenic peptide immunogenicity.;
NCI Metathesaurus CUI : CL416253;
Origin ID : C90569;
UMLS CUI : C2983769;
Semantic type(s)
- concept_is_in_subset
